Overexpression of p300 correlates with poor prognosis in patients with cutaneous squamous cell carcinoma

British Journal of Dermatology

Volumn 172, Issue 1, 2015, Pages 111-119

  Chen, M K ^a   Cai, M Y ^b   Luo, R Z ^b   Tian, X ^c   Liao, Q M ^a   Zhang, X Y ^a   Han, J D ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c GUANGZHOU INSTITUTE OF DERMATOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

E1A ASSOCIATED P300 PROTEIN; EP300 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; SKIN CARCINOMA; EPIDEMIOLOGY; HEAD AND NECK TUMOR; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; TUMOR VOLUME;

BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; E1A-ASSOCIATED P300 PROTEIN; EPIDEMIOLOGIC METHODS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR BURDEN;

EID: 84920775648     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13226     Document Type: Article

References (40)

1. Diepgen TL, Mahler V,. The epidemiology of skin cancer. Br J Dermatol 2002; 146 (Suppl. 61): 1-6.
2. Lomas A, Leonardi-Bee J, Bath-Hextall F,. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069-80.
3. Silverberg E, Boring CC, Squires TS,. Cancer statistics, 1990. CA Cancer J Clin 1990; 40: 9-26.
4. Madan V, Hoban P, Strange RC, et al,. Genetics and risk factors for basal cell carcinoma. Br J Dermatol 2006; 154 (Suppl. 1): 5-7.
5. Johnson TM, Rowe DE, Nelson BR, Swanson NA,. Squamous cell carcinoma of the skin (excluding lip and oral mucosa). J Am Acad Dermatol 1992; 26: 467-84.
6. Salehi Z, Mashayekhi F, Shahosseini F,. Significance of eIF4E expression in skin squamous cell carcinoma. Cell Biol Int 2007; 31: 1400-4.
7. Ramos J, Villa J, Ruiz A, et al,. UV dose determines key characteristics of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 2006-11.
8. de Vries E, van de Poll-Franse LV, Louwman WJ, et al,. Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermatol 2005; 152: 481-8.
9. Staples M, Marks R, Giles G,. Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: are primary prevention programs starting to have an effect? Int J Cancer 1998; 78: 144-8.
10. Trakatelli M, Ulrich C, del Marmol V, et al,. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007; 156 (Suppl. 3): 1-7.
11. Martorell-Calatayud A, Sanmartín Jimenez O, Cruz Mojarrieta J, Guillén Barona C,. Cutaneous squamous cell carcinoma: defining the high-risk variant. Actas Dermosifiliogr 2013; 104: 367-79.
12. Yanofsky VR, Mercer SE, Phelps RG,. Histopathological variants of cutaneous squamous cell carcinoma: a review. J Skin Cancer 2011; 2011: 210813.
13. Kundu TK, Palhan VB, Wang Z, et al,. Activator-dependent transcription from chromatin in vitro involving targeted histone acetylation by p300. Mol Cell 2000; 6: 551-61.
14. Goodman RH, Smolik S,. CBP/p300 in cell growth, transformation, and development. Genes Dev 2000; 14: 1553-77.
15. Fan S, Ma YX, Wang C, et al,. p300 modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res 2002; 62: 141-51.
16. Bandyopadhyay D, Okan NA, Bales E, et al,. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res 2002; 62: 6231-9.
17. Isharwal S, Miller MC, Marlow C, et al,. p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape. Prostate 2008; 68: 1097-104.
18. Debes JD, Sebo TJ, Lohse CM, et al,. p300 in prostate cancer proliferation and progression. Cancer Res 2003; 63: 7638-40.
19. Muraoka M, Konishi M, Kikuchi-Yanoshita R, et al,. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996; 12: 1565-9.
20. Gayther SA, Batley SJ, Linger L, et al,. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000; 24: 300-3.
21. Li M, Luo RZ, Chen JW, et al,. High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J Transl Med 2011; 9: 5.
22. International Agency for Research on Cancer. World Health Organization classification of tumours. Available at: http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb7/BB7.pdf (last accessed 20 November 2014).
23. Sobin LH, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours, 7th edn. Chichester: John Wiley & Sons, 2010.
24. Cai MY, Zhang B, He WP, et al,. Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci 2010; 101: 1543-9.
25. Zlobec I, Steele R, Terracciano L, et al,. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007; 60: 1112-16.
26. Ishihama K, Yamakawa M, Semba S, et al,. Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. J Clin Pathol 2007; 60: 1205-10.
27. Kurebayashi J, Otsuki T, Kunisue H, et al,. Expression levels of estrogen receptor-α, estrogen receptor-β, coactivators, and corepressors in breast cancer. Clin Cancer Res 2000; 6: 512-18.
28. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG,. Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis. Cell Res 2007; 17: 324-32.
29. Borrow J, Stanton VP Jr, Andresen JM, et al,. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996; 14: 33-41.
30. Bedford DC, Kasper LH, Fukuyama T, Brindle PK,. Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases. Epigenetics 2010; 5: 9-15.
31. Iyer NG, Ozdag H, Caldas C,. p300/CBP and cancer. Oncogene 2004; 23: 4225-31.
32. Hudelist G, Czerwenka K, Kubista E, et al,. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res Treat 2003; 78: 193-204.
33. De-Carvalho MC, Chimelli LM, Quirico-Santos T,. Modulation of fibronectin expression in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis. Braz J Med Biol Res 1999; 32: 583-92.
34. Mizuguchi Y, Specht S, Lunz JG 3rd, et al,. Cooperation of p300 and PCAF in the control of microRNA 200c/141 transcription and epithelial characteristics. PLoS ONE 2012; 7: e32449.
35. Iyer NG, Xian J, Chin SF, et al,. p300 is required for orderly G1/S transition in human cancer cells. Oncogene 2007; 26: 21-9.
36. Yan G, Eller MS, Elm C, et al,. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells. J Invest Dermatol 2013; 133: 2444-52.
37. Iyer NG, Chin SF, Ozdag H, et al,. p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc Natl Acad Sci USA 2004; 101: 7386-91.
38. Roozeboom MH, Lohman BG, Westers-Attema A, et al,. Clinical and histological prognostic factors for local recurrence and metastasis of cutaneous squamous cell carcinoma: analysis of a defined population. Acta Derm Venereol 2013; 93: 417-21.
39. Breuninger H, Brantsch K, Eigentler T, Häfner HM,. Comparison and evaluation of the current staging of cutaneous carcinomas. J Dtsch Dermatol Ges 2012; 10: 579-86.
40. Kyrgidis A, Tzellos TG, Kechagias N, et al,. Cutaneous squamous cell carcinoma (SCC) of the head and neck: risk factors of overall and recurrence-free survival. Eur J Cancer 2010; 46: 1563-72.